B Cell Lymphoma
Conference Coverage
Orelabrutinib could be ‘preferred’ BTK inhibitor for MCL
ORLANDO – Orelabrutinib produced an 86% response rate in a phase 2 trial and appears to be safer than ibrutinib.
Conference Coverage
Efficacy of postvenetoclax therapy may depend on prior agent exposure in CLL
ORLANDO – The multicenter study was aimed at addressing the knowledge gap around what therapy to use after venetoclax.
Conference Coverage
Off-the-shelf cellular therapy shows promise in the lab
ORLANDO – Findings from this preclinical research support moving forward with a phase 1 study of the therapy, as monotherapy or combined with...
From the Journals
Newly identified genetic changes contribute to transformation of follicular lymphoma
The case of a 36-year-old man whose low-grade follicular lymphoma transformed to B-ALL/LBL about 1 year after diagnosis sheds lights on the...
From the Journals
SOX11 shows value as diagnostic marker in MCL
The meta-analysis evaluated the diagnostic accuracy of SOX11 immunohistochemistry in mantle cell lymphoma.
From the Journals
Acalabrutinib may outperform other targeted therapies in MCL
The drug showed advantages over targeted monotherapies but was similar to rituximab-based combinations.
News from the FDA/CDC
FDA approves acalabrutinib for CLL, SLL treatment
The approval was made as part of Project Orbis, a collaboration among the FDA, the Australian Therapeutic Goods Administration, and Health Canada...
From the Journals
Frontline ibrutinib saves money over chemoimmunotherapy
An analysis of claims data for more than 1,000 patients with chronic lymphocytic leukemia shows that ibrutinib monotherapy is a less expensive...
From the Journals
Rituximab maintenance has a durable benefit in follicular lymphoma
At a median of 9 years of follow-up, progression-free survival was extended versus observation but there was no difference in overall survival.
From the Journals
CAR T-cell ‘cocktail’ may overcome antigen escape relapse
The pilot study used a sequential infusion of a third-generation chimeric antigen receptor T-cell “cocktail” targeting CD19 and CD22.
From the Journals
Adding polatuzumab extends survival in relapsed/refractory DLBCL
The combination offers a viable alternative for a group of patients with historically “dismal” outcomes, investigators said.